Navigation Links
Boffins Link Atkins Diet With Bowel Cancer

According to a new research, Atkins diet-low carbohydrate diet can increase the risks of bowel cancer. The research has discovered a decline in the production of a fatty acid in the gut , due to the consumption of carbohydrates.

The fatty acid butyrate, which protects against colorectal cancer, is produced by bacteria and helps in fighting cancerous cells. Researchers from the Rowett Research Institute, in Aberdeen, found that the widely practised Atkins Diet -can lead to four time reduction in the cancer-fighting bacteria.

"In the long run, it is possible that such diets could contribute to colorectal cancer. It is a preventable disease, and there is evidence that poor diet can increase your risk," Telegraph quoted Prof Harry Flint, who led the research, as saying.

The study conducted on 19 obese men, participants were given three diets with varied levels of carbohydrate- high, medium and low. The men on high carbohydrate diet consumed 400 gms of carbohydrate daily.

Men in the low carbohydrate consumption group consumed only 24 gms a day which is a normal amount in low-carbohydrate diets. Participants in the low group had a four-fold drop in the level of the cancer-fighting bacteria.

"The changes in butyrate production that we observed in this study are the largest ever reported in a human dietary trial," Flint said. Flint also said that a similar study on women is likely to show the same results.


'"/>




Page: 1

Related medicine news :

1. Fizzy Logic For A Perfect Drink: Courtesy Boffins
2. Boffins Identify Fifth Gene Behind Joubert Syndrome
3. Boffins Find Link Between Common Sleep Disorder and Hypertension
4. Boffins Identify Molecule That Might Treat Food Allergy
5. Boffins a Step Closer to Solving Puzzle of Lou Gehrigs Disease
6. Boffins Identify Gene That Helps Regulates Body Weight
7. Boffins Develop New Technique to Hunt Illness-causing Mutants in Non-gene DNA
8. Atkins Diet Damaging to Heart
9. Heart damage a consequence of Atkins’ Die
10. Atkins Diet Could Elevate Bad Cholesterol Levels, Warn Researchers
11. Hormone Could Be Answer To Atkins Diet Success
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Boffins Link Atkins Diet With Bowel Cancer

(Date:5/11/2008)...e/ -- As the global community observes,the destruc...yclone of all,time and the associated mounting fru... victims, the Alumni Myanmar Institutes of Medicin...importantly, successful-in initiating,medical care...000 people,are assumed dead. AMIMA has funded the ...
(Date:5/11/2008)... -- The winners of today,s Susan G.,Komen Pittsbur...ace Overall Winners Male: Pat McGuire, Charl...bein, Pittsburgh, Pa., 19:19, 2nd Place Overall W...: Anna Beck, Washington, Pa., 19:22, 3rd Place O..., Pa., 16:13 Female: Jessica Winter, Pittsbu...
(Date:5/11/2008)...nd for Unveiling of the New Name of the ...HICAGO, May 11 /PRNewswire/ -- Thousands of people...ntry were present for the unveiling of the,new nam...t cancer,organization, This year, Y-ME National B...h anniversary. In celebration of this landmark, Y-...
(Date:5/10/2008)...orts to Gain Clearance for Airlift of ... May 10 /PRNewswire-USNewswire/ -- An AmeriCares,e...today to assess the,crisis situation and continue ...ion,s airlift of 15 tons of essential medicines an...king closely with the World Health Organization to...
Breaking Medicine News(10 mins):Health News:Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims 2Health News:16th Annual Komen Pittsburgh Race for the Cure(R) Winners Announced 2Health News:Y-ME Makes Historic Announcement on Mother's Day 2Health News:Y-ME Makes Historic Announcement on Mother's Day 3Health News:AmeriCares Relief Worker Arrives in Myanmar 2
...on an earlier discovery that a gene called IRF6 is... palate, researchers at the University of Iowa Roy...d their colleagues have identified the function of...e Oct. 15 in Nature Genetics, reveal an unexpected...
... of home care for several thousands of elderly peo...ectors.// According to the Commission for Social ...re givers too rushed, giving insufficient time to ...giving 15 minute slots of help, before moving on t...
...t government-sponsored reports released on Tuesday... in spite of the risks due to contamination. These.... "Overall, for major health outcomes among adult... outweigh the risks. Somehow, this evidence has be...
...accine has proved to be efficient on animals accor...ntario.// "Perhaps we can cure HIV infection. Th...sity of Western Ontario. Clinical trials of the va...i million to be invested by Curocom Co., a compan...
Other Medicine News:Health News:Gene Involved In Common Birth Defect Also Regulates Skin Biology 2Health News:Gene Involved In Common Birth Defect Also Regulates Skin Biology 3Health News:Standards of Home Care for Elderly Needs Change 2Health News:Eating Fish has more Benefits than Risks 2
(Date:5/8/2008)...Call/ -- DATATRAK International, Inc.,(Nasdaq: DA... global,eClinical solutions for the clinical trial...or the first quarter of 2008., For the three mont...mately 41% to $2,088,000 and the Company reported ...n both a basic and diluted basis. These,results co...
(Date:5/8/2008)...tial of asenapine in the treatment of ...GTON, May 8 /- Schering-Plo... an overview of asenapine clinical trials,from the... Meeting of the,American Psychiatric Association i..., involving patients with bipolar I disorder and s...
(Date:5/8/2008)...e-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nasdaq...ator-sponsored,Phase I/II clinical trial of its le...combination with cytarabine in elderly patients wi... (AML) and high-risk,myelodysplastic syndromes (MD...on of Ellen K. Ritchie, M.D. at The Weill-Cornell ...
(Date:5/8/2008)...e-FirstCall/ -- AstraZeneca (NYSE:,AZN) today anno...plication,(sNDA) to the U.S. Food and Drug Adminis...rate) Extended-Release Tablets to seek approval fo...AD), including maintenance of,antianxiety effect. ...an,atypical antipsychotic medicine in GAD. The sub...
Breaking Medicine Technology:DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 1Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 2Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 3Purdue research finds similarities in dog human breast cancer pre malignant lesions 1245 4More Black Children Dying From Diabetes 6447 1More Black Children Dying From Diabetes 6447 2More Black Children Dying From Diabetes 6447 3Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 1Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 2Carnegie Mellon neuroscientist proposes new theory of brain flexibility 6442 3TriWest Executive Advisory Board Marks Its Fifth Year 6438 1TriWest Executive Advisory Board Marks Its Fifth Year 6438 2TriWest Executive Advisory Board Marks Its Fifth Year 6438 3
...O, Calif., May 02, 2007 /PRNewswire/ -- Ceregene, ...Phase 1 trial of,CERE-110, a gene therapy product ...the treatment of Alzheimer,s disease. After one,ye...who received,CERE-110 in the trial indicate that a...erated, and an interim analysis suggested that,the...
....C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeu...he immunosuppressive,properties of soluble CD83 at...eld in San Francisco, May 5-9. The presentations,w...e University of,Western Ontario., "These data sugg...ival in transplantation, and that it can also act,...
Other Medicine Technology:Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 2Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 3Ceregene Presents Interim Phase 1 Clinical Data of CERE-110 for the,Treatment of Alzheimer's Disease 4Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007 2
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
...s a national reference laboratory and a worldwide ...opment. ARUP offers an extensive test menu of high...d anatomic pathology. Owned by the University of U...half of the nation's university teaching hospitals...
Medicine Products: